Citizens reiterated its Market Outperform rating and $80 price target for CRISPR Therapeutics AG on Monday, following positive data presented at the European Society of Cardiology congress.
The brokerage cited CTX310, an ANGPTL3-targeting in vivo gene editor, which demonstrated sustained reductions in ANGPTL3 expression and key cardiovascular biomarkers. The treatment is positioned to advance into Phase 1b trials for severe hypertriglyceridemia, with early results suggesting efficacy comparable to monthly antisense oligonucleotide therapies or quarterly siRNA treatments but with the advantage of a single administration.
Citizens also highlighted the expanded U.S. label for CRISPR’s flagship therapy, CASGEVY, which now includes patients as young as two years old with sickle cell disease and transfusion-dependent beta-thalassemia. Vertex Pharmaceuticals, CASGEVY’s co-developer, presented additional data supporting regulatory submissions for children aged 5–11 in multiple jurisdictions.
The analyst firm estimated potential upside of approximately 39% for CRISPR Therapeutics, based on the current stock price of $57.72 and its $80 target. H.C. Wainwright similarly maintained a Buy rating and $80 price target, while Wall Street consensus remains broadly bullish, with 12 analysts recently raising earnings estimates.
Citizens also noted a 10–15% increase in the addressable market for CASGEVY due to the label expansion, reinforcing its positive outlook on the company’s pipeline and commercial prospects.
